The Dangers of Synthetic Marijuana: Rising Cases of Poisoning and Death

Aug.09.2022
The Dangers of Synthetic Marijuana: Rising Cases of Poisoning and Death
Synthetic marijuana is dangerous and can cause severe reactions such as seizures, heart problems, and death. It is a growing problem globally.

On August 5, 2015, a man was preparing to smoke K2, a synthetic marijuana drug, on a street in East Harlem, New York City.


Synthetic cannabis, sold under catchy names such as AK-47, K2, Spice, and Scooby Snacks, is far from being a dreamy substance. Most synthetic cannabinoids are packaged in electronic cigarettes, juices, or foods, and sold as dried plant material that has been sprayed with solvents containing laboratory-made psychoactive substances such as acetone, preservatives, or other chemicals.


According to data from the ToxIC case registry, cases of synthetic cannabis poisoning were on the rise between 2010 and 2015, with over 42,000 reported toxic exposure cases during that period. However, Tracy Klein, the assistant director of the Cannabis Policy, Research and Outreach Center at Washington State University in Vancouver, suggests that these numbers may now be decreasing in states where recreational marijuana use is allowed.


She was the lead author of a study that found that in states where recreational marijuana had been legalized between 2016 and 2019, calls to poison control center related to synthetic marijuana decreased by over one-third.


These products are in powder form, which can be sprayed or added to substances that look exactly like natural marijuana. Therefore, in party situations, I can see how someone could accidentally use it," said Klein, who is also an associate professor at the WSU College of Nursing.


However, according to the Centers for Disease Control and Prevention in the United States, people may also use synthetic cannabinoids "in an attempt to avoid positive drug screenings for employment, drug abuse treatment programs, or the criminal justice system.


A fatal issue/problem.


Over the past decade, thousands of people have been rushed to the emergency room due to marijuana use. According to the Centers for Disease Control and Prevention, some individuals have even died, including a 17-year-old boy who reportedly experienced cardiac arrest after using K2/spice marijuana once.


Experts say it is impossible to know what synthetic cannabinoids are actually present in purchased products or what other substances might be present in solvents used to soak and dry plants.


In April 2018, 153 people in Illinois fell ill and four died after using synthetic marijuana that was laced with rat poison. Later that year, in New Haven, Connecticut, K2 marijuana caused 95 people to become ill within two days. They experienced symptoms such as nausea, vomiting, lethargy, and loss of consciousness.


Klein explained that these synthetic products are officially known as "synthetic cannabinoid receptor agonists," which are different from synthetic marijuana products that have medical uses.


They do not appear in standard drug tests," she said. "The body also does not recognize them in any way that has a positive effect.


This research was published on Tuesday in the Clinical Toxicology Journal, analyzing data from the National Poison Data System between 2016 and 2019. The researchers discovered that over these three years, there were 7600 calls relating to the use of synthetic cannabinoids. Approximately 65% of calls made to poison centers concerned situations requiring medical care, with 61 fatalities reported.


A study has revealed that over half of the calls made to poison control centers (56%) were from states with restrictions on marijuana policies. According to the study, nearly one-third (38.6%) of calls were made from states that allow drug use for medical purposes, while 5.5% were from "permissive" states where recreational use is legal.


The working principle of synthetic cannabinoids.


The Centers for Disease Control and Prevention (CDC) stated that synthetic cannabinoids were first developed in the 1980s for the purpose of studying how tetrahydrocannabinol (THC), the psychoactive ingredient in marijuana, affects the brain in producing high levels.


Klein stated, "A specific synthetic marijuana was designed by a pharmaceutical company as a potential pain relief medication. People discovered that it was so potent and had so many side effects that it was not being abused.


Today, synthetic materials are mainly produced overseas and transported to the United States. In fact, according to the Centers for Disease Control, the first shipment of "goods identified as containing synthetic cannabinoids was seized at the U.S. border in 2008.


This is not just a problem in the United States. It has become an international issue", stated Klein. He pointed out that, as of February 2022, data on illegal markets listed at least 320 different types of synthetic cannabinoids being sold.


She added, "These are only those that have been reported and identified.


Klein stated that, although different from natural cannabis, synthetic compounds do indeed act on the same cannabinoid receptors as THC. However, due to the manner in which they bind to brain receptors, their potency can increase up to 100 times.


Exposure could lead to a range of neurological reactions, from mild to severe, such as agitation and depression in the central nervous system, which could even result in coma. The Centers for Disease Control and Prevention highlight other symptoms including "fatigue, irritability, confusion, dizziness, lack of coordination, inability to concentrate, stroke and seizures.


The agency stated that symptoms of mental illness include "hallucinations, delusions, psychosis, violent behavior, and suicidal thoughts." "Other physical signs and symptoms include shortness of breath, tachycardia, hypertension, severe nausea and vomiting, chest pain and heart attack, rhabdomyolysis (damaged muscles rupturing), kidney failure, and death.


The Disease Prevention and Control Center stated that there is no antidote for synthetic cannabinoid toxicity, and the long-term effects are still unknown. Treatment options include intravenous fluids, oxygen therapy, airway protection, and medication for anxiety and aggression, but these treatments are only supportive measures.


Announcement:


This article has been compiled from third-party sources and is intended solely for industry knowledge and exchange.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The translation of this article is solely for industry communication and research.


Due to limitations in the level of translation ability, the translated article may not express the same meaning as the original. Please refer to the original text for accuracy.


2FIRSTS fully aligns with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and international issues and positions.


The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report|CrossBar's High-Puff Vapes Draw Attention on Pennsylvania's 163-Product Directory as Link Between Earlier 1.3mL PMTA Filings and New 13mL Products Remains Unclear
Special Report|CrossBar's High-Puff Vapes Draw Attention on Pennsylvania's 163-Product Directory as Link Between Earlier 1.3mL PMTA Filings and New 13mL Products Remains Unclear
Pennsylvania began enforcing its electronic nicotine delivery system directory restrictions on October 19, 2026. Among 163 product listings recorded before enforcement, four CrossBar 20K disposables stood out with 13mL capacity, advertised puff counts of up to 20,000 and a flattened design distinct from conventional pod systems and compact disposables. Historical records identify earlier 1.3mL CrossBar products associated with Romo LLC, while newer 13mL products appeared in several state directories beginning in 2025 under entities including Blue Nine LLC. PMTA compliance expert Mr. K identified amendments and application ownership transfers as possible regulatory mechanisms, although neither has been confirmed in this case. Separately, Reynolds' $7.5 million acquisition of 16 PACHA products and related assets illustrates the commercial value of products linked to historic PMTA submissions.
Special Report
Oct.22
Product | Philip Morris Korea Launches TEREA Limona Pearl, Expanding Fresh Blend Capsule Lineup to Five
Product | Philip Morris Korea Launches TEREA Limona Pearl, Expanding Fresh Blend Capsule Lineup to Five
Philip Morris Korea launched TEREA Limona Pearl in South Korea on August 31, 2026, expanding the TEREA Fresh Blend capsule tobacco stick lineup from four variants to five. Designed for the IQOS ILUMA series, the new stick combines a capsule with what the company calls a Fresh Filter. Philip Morris Korea describes the product as offering an aromatic, refreshing flavor profile with a cooling sensation, with an additional fresh note released when the capsule is crushed. The recommended retail price is KRW 4,800 per pack, with sales through IQOS stores and convenience stores nationwide. No reliable evidence has been found that the same Limona Pearl SKU was previously officially launched in another major IQOS market.
Sep.01
Retail Case Study | Wisconsin Vape Market One Year After New Regulations: Johnny Vapes Reports 80% Sales Decline as Consumers Shift Online and Across State Lines
Retail Case Study | Wisconsin Vape Market One Year After New Regulations: Johnny Vapes Reports 80% Sales Decline as Consumers Shift Online and Across State Lines
According to WNCY on August 24, 2026, some independent vape retailers in Wisconsin say they have faced significant business pressure one year after new vape regulations took effect. Johnny Vapes, a retailer operating in northeast Wisconsin, said its store count fell from seven locations to four, sales declined by about 80%, and roughly 90% of its inventory was affected. Retailers said some consumers have shifted to online purchases or traveled to neighboring Michigan to buy vape products. The case highlights how local regulations can reshape retail operations, inventory management and consumer purchasing patterns.
Aug.28
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
AIRSCREAM’s production hub in the Czech Republic brings nicotine pouch manufacturing, e-liquid bottling, product documentation, warehousing and international logistics into one operation, giving brands and commercial partners a practical platform from which to launch, expand and enter new markets.
Market
Sep.16 by 2Firsts Perspectives
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
China Tobacco Plans CNY 60 Billion Investment in ICBC, Agricultural Bank as Strategic Ties Extend Beyond Equity
China Tobacco Plans CNY 60 Billion Investment in ICBC, Agricultural Bank as Strategic Ties Extend Beyond Equity
China National Tobacco Corporation and several subsidiaries plan to invest a combined CNY 60 billion ($8.7 billion) in share placements by Industrial and Commercial Bank of China and Agricultural Bank of China as strategic investors. The agreements extend beyond equity investment to corporate governance, banking services and supply-chain finance. The filings also disclose 2025 data on China Tobacco’s tax and profit contributions and industry scale.
Sep.07